PetMed Express shares traded higher in after-hours trading, changing hands at $1.21 and having touched an intraday high of $1.27, as investors processed a strategic partnership announcement alongside a mixed quarterly financial report released after the close of regular trading.
The company disclosed a white-label pharmacy agreement with Pet Supermarket. Under the arrangement, PetMed Express will supply prescription medications, preventatives and other health products to Pet Supermarket’s retail locations and its digital channels, using PetMed Express’s licensed pharmacy capabilities and its ability to ship to all 50 states.
On the earnings side, the company posted a net loss of $0.31 per share for the quarter ended September 30, 2026, a result that was meaningfully wider than analyst consensus. Revenue for the quarter came in at $35.8 million, missing estimates and declining roughly 19% from the comparable period a year earlier. Management attributed the revenue shortfall to lower prescription medication sales and an adverse shift in product mix.
Despite the headline shortfalls, the company’s loss narrowed versus the $8.5 million deficit recorded in the same quarter a year ago. Management said reduced general and administrative expenses and lower advertising spending contributed to that improvement. CEO Jeff Willard said the business had stabilized operations and reduced customer acquisition costs by 32% year-over-year, characterizing the quarter as a step toward building a leaner, more profitable company.
Sector and market context supported a cautiously constructive tone. Pet Valu, a peer in the pet retail space, reported stronger-than-expected third-quarter results on the same day, including a return to positive same-store sales, which provided some encouragement for the broader pet retail and services segment. The overall market backdrop was modestly positive during the session, with the S&P 500 up 0.1%, the Dow Jones Industrial Average up 0.1% and the NASDAQ rising 0.2%.
Investors appeared to balance the new Pet Supermarket white-label contract - which signals a continued push into B2B pharmacy services - against the disappointing top-line and earnings metrics. The partnership highlights a strategic emphasis on leveraging the company’s pharmacy infrastructure to distribute products through another retailer’s footprint and digital channels. At the same time, the quarterly results underscore ongoing headwinds from weaker prescription volume and product mix dynamics.
In sum, the combination of a potentially accretive retail partnership and evidence of cost discipline helped sustain interest in the shares in after-hours trade, even as revenue and headline earnings fell short of expectations.
Key points
- PetMed Express announced a white-label pharmacy agreement with Pet Supermarket to supply prescription medications, preventatives and health products through Pet Supermarket’s stores and digital platforms.
- The company reported a net loss of $0.31 per share for the quarter ended September 30, 2026, and revenue of $35.8 million, down roughly 19% year-over-year and below estimates.
- Operational improvements included a narrowed loss versus the prior-year quarter, reduced G&A and advertising expenses, and a 32% year-over-year cut in customer acquisition costs, according to CEO Jeff Willard.
Risks and uncertainties
- Revenue decline - The company’s revenue fell approximately 19% year-over-year, driven by lower prescription medication sales and an unfavorable product mix, which could continue to pressure margins and cash flow in the short term.
- Uncertainty over partnership impact - While the Pet Supermarket white-label agreement expands distribution channels, it is unclear how quickly and how materially the arrangement will offset recent revenue weaknesses.
- Market sensitivity - With investor sentiment influenced by broader market moves and peer performance in the pet retail sector, share price reactions may remain volatile around quarterly results and industry announcements.